ArticleScientific reports2020
Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 80 citations in OpenAlex.
- Interaction of β-Caryophyllene with a Simplified Membrane Model and Its Growth-Inhibitory Effect AgainstPathogens (Basel, Switzerland) · 2026Article
- Cannabinoid-Functionalized Glass Ionomer Cements: Structural Stability, Fluoride Release, and Antibiofilm Activity against Cariogenic Bacteria.ACS omega · 2026Article
- Therapeutic Potential of Cannabidiol in Dysbiosis-Related Oral Biofilm Diseases: Antibiofilm, Antivirulence and Host Response Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Effect of Microfluidization Technique on the Physicochemical Characteristics of Cannabidiol Nanoemulsions.Nanomaterials (Basel, Switzerland) · 2026Article
- Efficacy of Cannabidiol in Reducing Virulence ofInternational journal of molecular sciences · 2026Article
- Cannabidiol (CBD) InhibitsInternational journal of dentistry · 2026Article
- Antibacterial Effect of Cannabinoids on Bacteria Associated with Persistent Endodontic Infections.International journal of molecular sciences · 2025Article
- The importance of verifying biological activity predictions in metabolomics studies of natural products: A case study on antimicrobial properties ofPhytochemistry letters · 2025Article
- Anti-Infective Screening of Selected Nine Cannabinoids AgainstCurrent issues in molecular biology · 2025Article
- Antimicrobial Denture Material Synthesized from Poly(methyl methacrylate) Enriched with Cannabidiol Isolates.Molecules (Basel, Switzerland) · 2025Article
- Antimicrobial Potential of Cannabinoids: A Scoping Review of the Past 5 Years.Microorganisms · 2025Review
- Cannabidiol (CBD) Acts as an Antioxidant onAntibiotics (Basel, Switzerland) · 2025Article
- Utilization of Cannabidiol in Post-Organ-Transplant Care.International journal of molecular sciences · 2025Review
- Correlation between Chemical Fertilization Practices, Phytochemical Response, and Biological Activities ofCombinatorial chemistry & high throughput screening · 2025Review
- Antimicrobial and Anti-Biofilm Activity of Dichlorophen-Functionalized Gold Nanoparticles Against Carbapenem-ResistantInternational journal of nanomedicine · 2025Article
- Antibacterial phenolic compounds from the flowering plants of Asia and the Pacific: coming to the light.Pharmaceutical biology · 2024Review
- Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy AgainstAntibiotics (Basel, Switzerland) · 2024Review
- Cannabinoids in Integumentary Wound Care: A Systematic Review of Emerging Preclinical and Clinical Evidence.Pharmaceutics · 2024Review
- Exploring the versatile roles of the endocannabinoid system and phytocannabinoids in modulating bacterial infections.Infection and immunity · 2024Review
- Comprehensive Insight into Cutaneous Application of Hemp.Pharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cannabinoid cannabidiol (CBD) is characterised in this study as a helper compound against resistant bacteria. CBD potentiates the effect of bacitracin (BAC) against Gram-positive bacteria (Staphylococcus species, Listeria monocytogenes, and Enterococcus faecalis) but appears ineffective against Gram-negative bacteria. CBD reduced the MIC value of BAC by at least 64-fold and the combination yielded an FIC index of 0.5 or below in most Gram-positive bacteria tested. Morphological changes in S. aureus as a result of the combination of CBD and BAC included several septa formations during cell division along with membrane irregularities. Analysis of the muropeptide composition of treated S. aureus indicated no changes in the cell wall composition. However, CBD and BAC treated bacteria did show a decreased rate of autolysis. The bacteria further showed a decreased membrane potential upon treatment with CBD; yet, they did not show any further decrease upon combination treatment. Noticeably, expression of a major cell division regulator gene, ezrA, was reduced two-fold upon combination treatment emphasising the impact of the combination on cell division. Based on these observations, the combination of CBD and BAC is suggested to be a putative novel treatment in clinical settings for treatment of infections with antibiotic resistant Gram-positive bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.